Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Data ReadoutpositiveElevidysPositive

AI Analysis

Summary

Sarepta Therapeutics presented clinical data for Elevidys demonstrating clinically meaningful benefit in older DMD patients able to walk, with Jefferies analysts characterizing the company as a potential turnaround story with catalysts extending into 2027.

Outcome Details

Clinical data showing clinically meaningful benefit in older patients who are able to walk

Importance:6/10

Sentiment:

0.65

gene therapyDMDdata presentationanalyst commentary

Related Companies

$SRPT

Read the original article

Published by BioSpace on October 2, 2026 1:58 PM

Read Original